Skip to Content

Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG

Active Substance: tenecteplase
Common Name: tenecteplase
ATC Code: B01AD
Marketing Authorisation Holder: Boehringer Ingelheim International GmbH
Active Substance: tenecteplase
Status: Withdrawn
Authorisation Date: 2001-02-23
Therapeutic Area: Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.

The marketing authorisation for Tenecteplase Boehringer Ingelheim Pharma GmbH & Co. KG has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.